Female Reproductive & Breast

Urinary incontinence in women: types and management

Clinical Overview and When to Suspect Urinary Incontinence

— Strongly underreported — only ~25–50% of affected women raise it spontaneously. Screen actively at annual visits, Medicare wellness visits, and any geriatric assessment.

— Independently associated with falls, fractures, depression, skin breakdown, social isolation, and nursing home placement.

— Stress (leak with cough/laugh/exercise) — urethral hypermobility or intrinsic sphincter deficiency

— Urgency (sudden compelling urge, often large volumes) — detrusor overactivity, the storage component of overactive bladder (OAB)

— Mixed (features of both) — most common in women >60

— Overflow (incomplete emptying, dribbling) — detrusor underactivity or outlet obstruction (rare in women without prior anti-incontinence surgery or neuro disease)

— Functional (intact lower tract, impaired mobility/cognition)

— Gross hematuria or microhematuria

— New-onset incontinence with neurologic deficits (consider cauda equina, MS, cord compression)

— Recurrent UTI, suspected fistula (continuous leakage, often post-pelvic surgery or radiation), pelvic mass, or significant post-void residual

Board pearl: On Step 3, the first move for new incontinence in an older woman is not an anticholinergic — it is to screen for and reverse DIAPPERS causes (treat UTI, stop the diuretic dosed at bedtime, manage constipation) before labeling her with a chronic subtype.

Definition: Involuntary loss of urine that is objectively demonstrable and a social or hygienic problem. Affects ~25–45% of adult women; prevalence rises sharply after age 60 and exceeds 75% in nursing home residents.

Why it matters in primary care:

Major subtypes to keep in mind from the first question:

Red-flag features prompting urgent workup, not empiric therapy:

When to suspect a reversible/transient cause (mnemonic DIAPPERS): Delirium, Infection, Atrophic vaginitis, Pharmaceuticals, Psychiatric, Excess urine output (CHF, hyperglycemia, hypercalcemia), Restricted mobility, Stool impaction.

Presentation Patterns and Key History

— "Do you leak when you cough, sneeze, laugh, or exercise?" → stress

— "Do you get a sudden strong urge and can't make it to the toilet?" → urgency

— "Do you have both?" → mixed — identify the more bothersome component, because that drives initial therapy

— "Do you dribble continuously or feel you don't empty?" → overflow or fistula

— Pads per day, nocturia episodes, fluid intake (especially caffeine, alcohol, evening fluids), and impact on activities/sexual function

— A 3-day bladder diary is the highest-yield outpatient tool: voided volumes, leakage episodes, triggers, intake

— Parity, vaginal vs cesarean, operative delivery, birth weights, prolonged second stage

— Menopausal status, vaginal dryness/dyspareunia (genitourinary syndrome of menopause)

— Prior pelvic/anti-incontinence surgery, pelvic radiation, hysterectomy

— Diabetes (polyuria, neuropathy), CHF (nocturnal diuresis when supine), COPD (chronic cough → stress leakage), obesity, stroke, Parkinson, MS, dementia, depression

— Loop diuretics (urgency, polyuria)

— Alpha-blockers (decrease urethral tone → stress leakage)

— Cholinesterase inhibitors (urgency)

— Sedatives/opioids (functional incontinence, retention)

— ACEi (cough-induced stress leakage), SGLT2 inhibitors (osmotic polyuria), gabapentinoids/TZDs (edema → nocturia)

Step 3 management: When a woman reports mixed symptoms, ask which leakage bothers her most — that single answer determines whether you start pelvic floor therapy + pessary/surgery referral (stress-dominant) vs behavioral therapy + beta-3 agonist or anticholinergic (urge-dominant).

Targeted history is the single most useful diagnostic tool — it correctly classifies subtype in ~80% of women without urodynamics.

Key triage questions:

Quantify burden:

Obstetric/gynecologic history:

Medical comorbidities driving incontinence:

Medication review — high-yield offenders:

Physical Exam Findings and Bedside Assessment

— Gait, transfer ability, dexterity to manage clothing — functional incontinence diagnoses are made here

— Mini-Cog or MoCA if cognitive impairment suspected; depression screen (PHQ-2)

— BMI (weight loss of even 5–10% reduces incontinence episodes in obese women — a Level 1 evidence intervention)

— Atrophic vaginitis: pale, thin, friable mucosa, loss of rugae → treat with topical vaginal estrogen (improves urgency, frequency, recurrent UTIs, and stress symptoms)

— Pelvic organ prolapse: cystocele, rectocele, uterine prolapse — graded with POP-Q; advanced prolapse can mask or cause stress incontinence ("kinking" of urethra)

— Pelvic floor tone: ability to perform voluntary Kegel contraction — predicts response to pelvic floor muscle training (PFMT)

— Masses, fistula openings, urethral diverticulum (tender anterior vaginal wall mass with expressible discharge)

— With comfortably full bladder, supine or standing, ask patient to cough forcefully — immediate spurt of urine = positive for stress incontinence (high specificity)

— Delayed leakage suggests cough-induced detrusor overactivity

— Bladder ultrasound or in-and-out catheter within 10 minutes of voiding

— PVR <150 mL is reassuring; >150–200 mL suggests overflow/retention and contraindicates anticholinergic therapy

Key distinction: A positive cough stress test plus low PVR essentially confirms stress incontinence and lets you proceed to treatment without urodynamics in straightforward cases.

General and functional assessment:

Abdominal exam: Suprapubic mass or distended bladder (overflow), surgical scars, organomegaly contributing to intra-abdominal pressure.

Pelvic exam — must do before treatment:

Cough stress test:

Post-void residual (PVR):

Neurologic exam: Perineal sensation (S2–S4), anal tone, bulbocavernosus reflex, lower extremity strength/reflexes — abnormalities point to neurogenic bladder.

Diagnostic Workup — Initial Labs and Bedside Studies

— Urinalysis with microscopy — rule out infection, hematuria, glycosuria, proteinuria

— Post-void residual (PVR) — bladder scan preferred; cath if scanner unavailable

— 3-day bladder diary — voided volumes, leakage episodes, fluid intake

— Targeted history-driven labs only

— Pyuria + bacteriuria + symptoms → treat UTI, then reassess incontinence after 2–4 weeks (often resolves or markedly improves; this is the "I" in DIAPPERS)

— Asymptomatic bacteriuria in non-pregnant women is not treated, even if incontinent

— Microhematuria (≥3 RBC/hpf): AUA risk-stratify; women >50 or with smoking history → cystoscopy + upper tract imaging (CT urogram) to rule out urothelial malignancy

— Glycosuria → check fasting glucose/A1c (osmotic diuresis as a reversible cause)

— BMP (polyuria, suspected hypercalcemia, renal disease)

— Glucose/A1c (new polyuria)

— TSH (rare contributor via polyuria or autonomic effects)

— Urine cytology only for high-risk hematuria

— <50 mL: normal

— 50–150 mL: borderline, repeat

— >150–200 mL: significant retention — search for outlet obstruction (severe prolapse, prior sling), detrusor underactivity (DM, neuro), or medication effect (anticholinergics, opioids)

— Urodynamics, cystoscopy, or pelvic ultrasound are not first-line in uncomplicated stress, urge, or mixed incontinence — reserve for failed therapy, prior anti-incontinence surgery, neurogenic findings, hematuria, or planned surgery.

Board pearl: A common Step 3 distractor is ordering urodynamics or cystoscopy upfront — the correct answer for a typical primary-care presentation is UA + PVR + bladder diary, then a behavioral trial.

Required first-line workup for every woman with new or undifferentiated incontinence:

Urinalysis interpretation:

Other labs only if clinically indicated:

PVR thresholds and meaning:

What you do NOT need routinely:

Diagnostic Workup — Advanced or Confirmatory Studies

— Components: uroflowmetry, cystometry (fills bladder while measuring detrusor and abdominal pressures), pressure-flow study, EMG, leak point pressures

— Indications:

— Discordance between symptoms and exam

— Failure of first-line therapy

— Prior anti-incontinence or pelvic surgery

— Suspected neurogenic bladder (MS, spinal cord injury, Parkinson)

— Significant pelvic organ prolapse before surgical planning

— Significantly elevated PVR or suspected outlet obstruction

— Findings:

— Detrusor overactivity → confirms urge incontinence

— Reduced abdominal/Valsalva leak point pressure → intrinsic sphincter deficiency (consider sling vs bulking)

— Indicated for microhematuria meeting AUA criteria, recurrent UTI without explanation, suspected fistula, foreign body (mesh erosion), bladder pain, or prior failed surgery

— CT urogram or MR urogram — hematuria workup, suspected upper tract pathology, fistula evaluation

— Pelvic ultrasound — suspected mass, urethral diverticulum (MRI is more sensitive)

— Voiding cystourethrogram — suspected vesicovaginal fistula or significant prolapse

— Urogynecology or female pelvic medicine: complex prolapse, failed conservative therapy, surgical candidate

— Neurology: new neurologic signs, suspected demyelinating disease, cord pathology

— Urology: hematuria workup, suspected malignancy, fistula, mesh complications

— Document a trial of at least 8–12 weeks of conservative therapy before invasive evaluation in uncomplicated cases — payers and guidelines align here.

Step 3 management: Order urodynamics when the answer to surgery depends on it — e.g., before a midurethral sling in a woman with mixed symptoms and prior pelvic surgery, or when symptoms and exam disagree. Otherwise, behavioral therapy first.

Urodynamic testing (UDS):

Cystourethroscopy:

Imaging:

Specialized referral triggers:

Quality measures:

Risk Stratification and First-Line Management Logic

— Lifestyle modification:

— Weight loss (5–10% body weight reduces episodes by ~50% in obese women — strongest evidence base)

— Reduce caffeine, alcohol, carbonated beverages

— Smoking cessation (chronic cough → stress leakage; nicotine → urgency)

— Treat constipation (fiber, hydration, stool softeners)

— Fluid management: 1.5–2 L/day; reduce evening intake for nocturia

— Timed/scheduled voiding (every 2–3 hours)

— Pelvic floor muscle training (PFMT/Kegels):

— First-line for stress, urge, and mixed incontinence

— 8–12 weeks minimum; effectiveness depends on technique — refer to pelvic floor physical therapy if available, especially for elderly or those unable to identify correct muscles

— Biofeedback or vaginal cones can augment

— Bladder training (for urgency): scheduled voiding with progressively increased intervals, urge suppression techniques

— Stress: PFMT ± weight loss; consider pessary (continence ring) for symptomatic relief, especially in surgical-poor candidates

— Urgency/OAB: Behavioral therapy + bladder training; add pharmacotherapy if inadequate after 6–12 weeks

— Mixed: Treat the more bothersome component first

— Overflow: Address obstruction (prolapse reduction, treat impaction) or underactive detrusor (clean intermittent catheterization, stop offending drugs)

— Functional: Toileting schedule, bedside commode, easier clothing, caregiver education

Board pearl: The exam will reward behavioral + lifestyle therapy before drugs in nearly every uncomplicated case — anticholinergics or surgery as first move is almost always wrong.

Universal first-line interventions — offer to every woman regardless of subtype:

Subtype-directed first-line:

Adjunctive: Topical vaginal estrogen for postmenopausal women with genitourinary syndrome of menopause — improves urgency, frequency, dysuria, and recurrent UTI; safe even in many breast cancer survivors after shared decision-making.

Pharmacotherapy — First-Line Drug Regimens

— Antimuscarinics (anticholinergics): oxybutynin, tolterodine, solifenacin, darifenacin, trospium, fesoterodine

— Mechanism: block M2/M3 receptors on detrusor → reduce involuntary contractions

— Side effects: dry mouth, constipation, blurred vision, urinary retention, cognitive impairment (especially oxybutynin IR — crosses BBB)

— Contraindications: narrow-angle glaucoma, gastric retention, significant PVR

— Beta-3 adrenergic agonists: mirabegron, vibegron

— Mechanism: stimulate β3 receptors → detrusor relaxation during storage

— Side effects: hypertension (check BP), headache, nasopharyngitis

— Preferred in elderly and patients with cognitive concerns or anticholinergic burden

— Avoid mirabegron in uncontrolled HTN (>180/110)

— Start extended-release agent (better tolerability)

— Titrate over 4–8 weeks; trial each agent ≥4 weeks before declaring failure

— Combination therapy (antimuscarinic + mirabegron) for refractory OAB before invasive options

— Duloxetine (SNRI) — approved in Europe, not FDA-approved for SUI in US; modest benefit, used off-label especially when comorbid depression

— Topical vaginal estrogen — adjunct in postmenopausal women; systemic oral estrogen worsens incontinence (WHI data) and is contraindicated for this indication

— Counsel that meaningful response takes 4–8 weeks

— ~50% discontinuation at 6 months due to side effects or inadequate effect

— Reassess at 3 months; consider step-up to procedural therapy if refractory

Step 3 management: In a woman >70 or with mild cognitive impairment and urge incontinence, choose mirabegron over oxybutynin — Beers Criteria flag anticholinergics for cognitive risk and falls.

Urgency incontinence / overactive bladder — drug classes:

Selection logic:

Stress incontinence — pharmacology is limited:

Overflow incontinence: No primary drug therapy; remove offending agents (anticholinergics, opioids, calcium channel blockers), CIC for retention, treat underlying obstruction.

Treatment-trial framing:

Procedural and Surgical Management

— Midurethral sling (MUS) — gold standard surgical therapy

— Retropubic (TVT) or transobturator (TOT) approach

— Cure rates ~80–90% at 1 year; durable at 5–10 years

— Risks: bladder/urethral injury, voiding dysfunction, mesh exposure (~2–3%), groin pain (TOT), de novo urgency

— Pubovaginal autologous fascial sling — for women preferring no mesh or with prior mesh complications

— Burch colposuspension — open or laparoscopic; useful when undergoing concurrent abdominal surgery

— Urethral bulking agents (collagen, calcium hydroxylapatite) — office-based, lower efficacy, good for intrinsic sphincter deficiency or surgical-poor candidates

— Pessary (continence ring) — non-surgical, immediately effective in many; requires self-care or periodic office changes

— Intradetrusor onabotulinumtoxinA (Botox) injection:

— Cystoscopic injection; effective 6–9 months

— Risk of urinary retention requiring CIC (~5–6%), UTI

— Percutaneous tibial nerve stimulation (PTNS): weekly office sessions × 12 weeks, then maintenance

— Sacral neuromodulation (InterStim): implanted device modulating S3 nerve root; good for refractory urge and non-obstructive retention

Board pearl: For refractory OAB, the third-line ladder is Botox → PTNS → sacral neuromodulation — choose Botox in younger women willing to self-cath if needed; sacral neuromodulation in those wanting durable, drug-free therapy.

Stress incontinence — procedural options (after failed conservative therapy):

Urgency incontinence — third-line therapies (after failed behavioral + 2 drug trials):

Pelvic organ prolapse surgery: Address concurrent prolapse; occult stress incontinence may unmask after prolapse repair — discuss prophylactic anti-incontinence procedure.

Overflow/retention: Clean intermittent catheterization (CIC) is preferred over indwelling Foley; treat reversible causes; rare surgical options for selected obstruction.

Preoperative considerations: Urodynamics for mixed symptoms, prior failed surgery, or significant prolapse; counsel on mesh, voiding dysfunction risk, and persistent urgency.

Special Populations — Elderly and Renal/Hepatic Impairment

— Often multifactorial: detrusor overactivity with impaired contractility (DHIC) is common — urgency and incomplete emptying

— Higher rates of mixed and functional incontinence

— Goals shift toward function, dignity, caregiver burden, skin integrity, and fall prevention rather than complete dryness

— Delirium screening with new incontinence in hospitalized elders

— Stool impaction is frequently missed — perform rectal exam

— Polypharmacy review at every visit

— Avoid oxybutynin IR — high anticholinergic burden, BBB penetration, cognitive impairment, increased dementia risk with cumulative exposure (Beers Criteria)

— Prefer trospium (quaternary amine, doesn't cross BBB), darifenacin (M3-selective), or mirabegron/vibegron (no anticholinergic effect)

— Start low, titrate slowly; reassess cognition at follow-up

— Check BP with mirabegron; avoid if SBP >180 or DBP >110

— Solifenacin: max 5 mg/day if CrCl <30

— Trospium: reduce dose or extend interval if CrCl <30; avoid ER formulation

— Mirabegron: max 25 mg if CrCl 15–29 or severe hepatic impairment; avoid if CrCl <15

— Fesoterodine: max 4 mg if CrCl <30

— Most antimuscarinics require dose reduction in moderate hepatic impairment; avoid in severe (Child-Pugh C)

— Mirabegron: avoid in severe hepatic impairment

— Bedside commode, raised toilet seats, grab bars, night lighting, easy-remove clothing

— Prompted voiding every 2–3 hours in cognitively impaired nursing home residents — reduces episodes ~30%

— Treat constipation, optimize mobility (PT), manage CHF and diabetes to reduce nocturnal polyuria

Step 3 management: A 78-year-old woman with mild dementia and urge incontinence — first step is scheduled toileting and review meds (stop donepezil-cholinesterase mismatch with anticholinergic, address diuretic timing), then mirabegron if pharmacotherapy needed.

Geriatric incontinence — distinctive features:

Reversible contributors to prioritize (DIAPPERS):

Drug selection in the elderly:

Renal impairment dosing:

Hepatic impairment:

Functional and environmental interventions:

Special Populations — Pregnancy, Postpartum, and Other Subgroups

— Incontinence affects ~40–60% of pregnant women, mostly stress type from increased intra-abdominal pressure and pelvic floor loading

— Workup: rule out UTI (treat asymptomatic bacteriuria in pregnancy — unlike non-pregnant), assess for preterm labor if associated with fluid leakage (consider rupture of membranes)

— Management: PFMT during and after pregnancy reduces incontinence at 6–12 months postpartum (strong evidence)

— Avoid antimuscarinics and mirabegron in pregnancy (limited data; category C-equivalent)

— Most stress incontinence improves spontaneously by 6–12 months

— Persistent symptoms at 3 months → start supervised PFMT; defer surgery until childbearing complete

— Risk factors: vaginal delivery, operative delivery (forceps > vacuum), prolonged second stage, high birth weight, third/fourth-degree laceration

— Cesarean delivery reduces but does not eliminate risk

— Genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, urgency, recurrent UTI

— Topical vaginal estrogen (cream, tablet, ring) — first-line; safe for most women including many breast cancer survivors after oncology discussion

— Avoid systemic oral estrogen for incontinence — WHI showed increased incontinence

— MS, Parkinson, stroke, spinal cord injury → neurogenic bladder; urodynamics often needed

— Risk of upper tract damage with high storage pressures — urology referral

— Stress incontinence common in high-impact sports (gymnastics, running, trampoline)

— PFMT highly effective; tampon or pessary during exercise as bridge

— Aromatase inhibitors worsen GSM → topical estrogen requires shared decision with oncology; vaginal DHEA or moisturizers as alternatives

Board pearl: Vaginal estrogen helps urinary symptoms; systemic estrogen makes them worse — this reversal trips up test-takers.

Pregnancy:

Postpartum:

Perimenopause/postmenopause:

Women with neurologic disease:

Athletes and young women:

Breast cancer survivors:

Complications and Adverse Outcomes

— Incontinence-associated dermatitis (IAD): erythema, maceration, erosion of perineal skin; predisposes to candidiasis and pressure injury

— Prevention: barrier creams (zinc oxide, dimethicone), pH-balanced cleansers, prompt pad changes, breathable products

— Recurrent UTIs: especially with incomplete emptying or post-void catheterization

— Falls and fractures: nocturia is an independent risk factor for hip fracture in elderly women — addressing nocturia is a fall-prevention intervention

— Sleep disruption and depression: nocturia >2 episodes/night strongly correlates with poor sleep quality

— Social withdrawal, sexual dysfunction, caregiver burden

— Independent predictor of nursing home placement in community-dwelling elderly

— Antimuscarinics: cognitive impairment (cumulative dementia risk), urinary retention, constipation, dry mouth, narrow-angle glaucoma exacerbation

— Mirabegron: hypertension, tachycardia, rare angioedema; CYP2D6 interactions (caution with metoprolol, flecainide)

— Botox: urinary retention requiring CIC (~5–6%), UTI; counsel before injection

— Sling surgery:

— Voiding dysfunction or retention (5–10%)

— De novo urgency (5–15%)

— Mesh exposure/extrusion (~2–3%) — vaginal bleeding, dyspareunia, partner discomfort; may require revision

— Bladder/urethral injury intraoperatively

— Groin pain (transobturator approach)

— Recurrent stress incontinence over time

— Pessary: vaginal erosion, discharge, odor if not maintained; rare fistula with neglected pessary

— Pad and product costs, missed work, caregiver time

— Drug discontinuation rates 50–70% at 1 year — drives reconsideration of approach

Key distinction: Voiding dysfunction after a sling vs de novo OAB — retention with elevated PVR suggests sling too tight (consider loosening/cutting); urgency with normal PVR is de novo OAB managed medically.

Direct medical complications of incontinence:

Psychosocial and quality-of-life consequences:

Treatment-related complications:

Health-system complications:

When to Escalate Care — Referral and Inpatient Triage

— Acute urinary retention: painful distended bladder, PVR >300 mL, inability to void → catheterize, search for cause (medication, impaction, neurologic, post-op)

— New incontinence with neurologic signs: saddle anesthesia, lower extremity weakness, bowel incontinence → emergent MRI to rule out cauda equina syndrome or cord compression

— Gross hematuria with clots → urgent urology, possible continuous bladder irrigation

— Suspected fistula (continuous leakage, often after pelvic surgery, prolonged labor in resource-limited settings, or pelvic radiation) → urogynecology/urology referral

— Failure of 8–12 weeks of conservative + first-line pharmacotherapy

— Hematuria meeting AUA evaluation criteria

— Recurrent UTI without clear cause

— Significant pelvic organ prolapse (POP-Q stage ≥2 with symptoms)

— Suspected neurogenic bladder

— Prior anti-incontinence or pelvic surgery

— Significant PVR (>150–200 mL)

— Patient preference for procedural therapy

— New focal deficits, suspected MS (young woman with optic, sensory, or motor symptoms plus bladder), Parkinsonian features, suspected normal pressure hydrocephalus (wet-wacky-wobbly triad)

— Frail elderly with multifactorial incontinence, polypharmacy, cognitive impairment, or caregiver-management challenges

— All women who cannot identify or correctly contract pelvic floor muscles on exam, athletes, postpartum women with persistent symptoms

CCS pearl: On the CCS case of an elderly hospitalized woman with new urinary incontinence, order UA, PVR, medication reconciliation, rectal exam for impaction, and cognitive screen before any drug — the case rewards reversible-cause workup.

Urgent/emergent escalation:

Urology or urogynecology referral indications (outpatient):

Neurology referral:

Geriatrics referral:

Pelvic floor physical therapy referral:

Key Differentials — Within the Incontinence Category

— Leakage with cough/sneeze/laugh/exertion; no urge

— Mechanism: urethral hypermobility (most common) or intrinsic sphincter deficiency (low Valsalva leak point pressure, often after prior surgery, radiation, or aging)

— Diagnostic clincher: positive cough stress test with low PVR

— Sudden urge, often unable to reach toilet, sometimes triggered by "key in lock," running water

— Mechanism: detrusor overactivity (idiopathic or neurogenic)

— Often nocturia, frequency >8/day

— Features of both; predominant component drives initial therapy

— More common with age; treatment often combined

— Continuous dribbling, hesitancy, weak stream, sensation of incomplete emptying

— Causes: detrusor underactivity (diabetic cystopathy, chronic over-distension, neurologic), outlet obstruction (severe prolapse "kinking" the urethra, prior sling too tight, urethral stricture — rare in women)

— Elevated PVR is the hallmark

— Intact lower tract; impairment is mobility, dexterity, cognition, or environment (e.g., delirium, severe arthritis, restrained in hospital bed)

— Treat by modifying environment and underlying impairment

— Constant leakage day and night, often without sensation

— Causes: vesicovaginal or ureterovaginal fistula (post-hysterectomy, obstructed labor in developing world, pelvic radiation, malignancy)

— Diagnosis: dye tests (tampon test with oral phenazopyridine and intravesical methylene blue), cystoscopy, CT urogram

— Triad: dysuria, post-void dribbling, dyspareunia ("3 Ds"); tender anterior vaginal wall mass with expressible discharge; MRI confirms

Key distinction: Continuous leakage without sensation = think fistula; continuous dribbling with retention = think overflow.

Stress urinary incontinence (SUI):

Urgency urinary incontinence / OAB-wet:

Mixed incontinence:

Overflow incontinence:

Functional incontinence:

Continuous incontinence / fistula:

Urethral diverticulum:

Key Differentials — Other Categories Mimicking Incontinence

— Acute dysuria, frequency, urgency ± incontinence

— Diagnose with UA + culture; treat → reassess incontinence

— Recurrent UTI in postmenopausal women → vaginal estrogen, address PVR, consider prophylaxis

— Painless gross or microscopic hematuria, irritative voiding symptoms, especially in smokers and women >50

— Workup: cystoscopy + CT urogram + cytology

— Suprapubic pain worsening with filling, relieved by voiding; frequency/urgency without infection

— Often confused with OAB; pain is the distinguishing feature

— Polyuria, polydipsia, glycosuria (DM) or dilute urine (DI)

— Check glucose, urine osmolality

— Nocturnal redistribution of edema → nocturnal polyuria and nocturia

— Treat HF, time loop diuretic earlier in the day

— Nocturia via elevated atrial natriuretic peptide; consider in obese women with snoring, daytime sleepiness

— Multiple sclerosis (young woman, episodic neuro symptoms, urgency/retention/incomplete emptying)

— Parkinson disease (urgency, frequency from detrusor overactivity)

— Stroke (urgency post-stroke), spinal cord lesions, cauda equina, normal pressure hydrocephalus (wet-wacky-wobbly)

— Diuretics, alpha-blockers (prazosin, tamsulosin — used in some women for retention; can worsen SUI), ACEi cough, SGLT2 inhibitors, gabapentinoids, cholinesterase inhibitors

— Large fibroids, ovarian masses, gravid uterus → frequency, retention, or stress leakage from mass effect

Board pearl: A 35-year-old woman with new urgency, occasional vision blurring, and lower extremity paresthesias — work up MS with MRI brain/spine, not just OAB.

Urinary tract infection:

Bladder malignancy:

Bladder pain syndrome / interstitial cystitis:

Diabetes mellitus and insipidus:

Heart failure:

Obstructive sleep apnea:

Neurologic disease:

Medication-induced:

Pelvic masses and pregnancy:

Long-Term Plan and Secondary Prevention

— Reinforce lifestyle gains at every visit: weight, caffeine, smoking, fluid timing, bowel regimen

— Continue pelvic floor exercises long-term — gains reverse with discontinuation

— Reassess medications annually for ongoing need and side effect burden

— Continue effective drug at lowest effective dose

— Drug holiday trials every 6–12 months to assess ongoing need (some women have sustained behavioral gains)

— Rotate agents if tachyphylaxis or intolerance

— Step up to third-line therapy if pad usage and bother persist despite optimized first/second line

— Continue PFMT post-sling — augments durability

— Counsel that ~10–20% will have recurrence over 10 years; document baseline pad use to compare

— Continue topical vaginal estrogen indefinitely if effective and well tolerated — no endometrial monitoring needed at typical low doses; reassess shared decision-making periodically

— Diabetes: target A1c per individualized goal — glycosuria worsens incontinence

— CHF: optimize volume status, time diuretics in morning/afternoon

— OSA: CPAP improves nocturia

— Constipation: maintenance fiber, hydration, stool softeners

— Continue age-appropriate cancer screening (cervical, breast, colon)

— Bone health: women with falls/fracture risk from nocturia and incontinence-related falls need DEXA, vitamin D, calcium per USPSTF/Endocrine Society

— Medicare and most insurers cover limited absorbent products via state Medicaid or supplemental plans only — clarify coverage

— Continence support groups, NAFC resources, pelvic floor PT for refresher courses

Step 3 management: At each annual visit for a woman on OAB therapy, reassess symptom burden, side effects, cognitive function, BP (if mirabegron), and need for continued medication — deprescribe when behavioral gains permit.

Maintenance principles:

Stepped maintenance for OAB:

Stepped maintenance for SUI post-procedure:

Genitourinary syndrome of menopause:

Comorbid disease optimization for secondary prevention:

Vaccinations and screening:

Patient resources and durable goods:

Follow-Up, Monitoring, and Counseling

— 2–4 weeks: phone or visit to reinforce behavioral therapy, troubleshoot side effects, confirm correct PFMT technique

— 6–8 weeks: assess symptom response with repeat bladder diary; titrate drug if partial response

— 3 months: decision point — continue, switch agent, add combination, or escalate to procedural therapy

— 6–12 months: annual reassessment if stable

— Antimuscarinics: cognitive screen (Mini-Cog or MoCA) at baseline and annually in elderly; constipation, dry mouth, PVR if new retention symptoms; ocular pressure screening if narrow-angle glaucoma history

— Mirabegron/vibegron: BP at baseline, 4–8 weeks, then periodically; review CYP2D6-metabolized drugs

— Topical estrogen: assess vaginal symptoms; no routine endometrial biopsy needed at standard low doses unless bleeding

— Post-sling: voiding trial before discharge; PVR at 2-week visit; assess for retention, de novo urgency, mesh complaints, dyspareunia at 6 weeks and 3 months

— Post-Botox: PVR at 2 weeks; counsel patient on self-catheterization plan

— Set realistic expectations: 50% reduction in episodes is a clinically meaningful response; complete dryness is not always achievable

— Discuss trade-offs: efficacy vs anticholinergic burden, surgery risks vs durability, pessary vs sling

— Use validated tools: ICIQ-UI Short Form, UDI-6, IIQ-7 to track response

— Refer to pelvic floor PT for biofeedback, electrical stimulation if PFMT inadequate

— Bladder retraining diaries for relapse

— Smoking cessation and weight management referrals

— Track pad use, episodes/week, quality of life scores in chart for population health metrics

Board pearl: Reassess at 3 months — that's when the exam wants you to either declare success, switch agents, or escalate to third-line therapy.

Follow-up cadence after starting therapy:

Monitoring parameters by therapy:

Counseling and shared decision-making:

Rehab and behavioral reinforcement:

Documentation for value-based care:

Ethical, Legal, and Patient Safety Considerations

— Mesh sling counseling is a particular legal and ethical focus — FDA has issued safety communications about transvaginal mesh for prolapse (banned in 2019 for POP) but midurethral slings for SUI remain standard of care

— Document: benefits, alternatives (no surgery, pessary, autologous fascial sling, bulking), specific risks (mesh exposure, dyspareunia, voiding dysfunction, de novo urgency, need for revision), and patient questions

— Provide written materials; allow time for decision; document shared decision-making

— Elderly women with cognitive impairment may need surrogate consent for invasive procedures; ensure goals of care align with quality of life

— Avoid anticholinergics in patients with dementia even if surrogate requests — there is an ethical obligation to balance caregiver convenience with patient cognitive harm

— Avoid indwelling Foley catheters for incontinence management — major source of CAUTI; use external female catheters (PureWick), scheduled toileting, condom-style devices

— CAUTI is a CMS "never event" with reimbursement consequences — institutional Foley protocols required

— Falls associated with urgent nighttime toileting — environmental modifications (lighting, bedside commode, non-skid floors) are quality measures

— New incontinence in a dependent elder may signal neglect (untreated UTI, dehydration, immobility, lack of toileting assistance) — screen for elder abuse; mandatory reporting in most states

— Pelvic trauma or unusual findings on exam → consider intimate partner violence or sexual assault; report per state law

— Discharge from hospital with new incontinence — ensure outpatient follow-up scheduled, PVR documented, Foley removed before discharge whenever possible, and home services arranged

— Medication reconciliation: many newly prescribed drugs (loop diuretics, opioids, anticholinergics for sleep) cause or worsen incontinence after discharge

— Incontinence carries stigma — examine and discuss privately; avoid hallway discussions; offer same-gender chaperones for pelvic exams

Step 3 management: When a hospitalized elder is discharged to a SNF on a Foley placed "for incontinence," the correct action is to remove the Foley before transfer, document a voiding trial and PVR, and communicate a continence plan to the receiving facility — leaving the Foley in is a patient-safety failure.

Informed consent for procedural therapy:

Capacity and surrogate decision-making:

Patient safety in hospitalized and long-term care patients:

Mandatory reporting and abuse screening:

Transitions of care:

Privacy and dignity:

High-Yield Associations and Rapid-Fire Facts

— <60: stress

— >60: mixed, then urge

Board pearl: If a stem mentions "leaks with coughing AND laughing" — it's stress; "sudden strong urge with running water" — it's urge; "leaks all the time after hysterectomy" — it's fistula.

Mnemonic for reversible causes — DIAPPERS: Delirium, Infection, Atrophic vaginitis, Pharmaceuticals, Psychiatric, Excess output (CHF, hyperglycemia, hypercalcemia), Restricted mobility, Stool impaction.

Most common type by age:

Weight loss of 5–10% reduces incontinence episodes ~50% — strongest lifestyle intervention.

Vaginal estrogen helps; oral estrogen harms urinary symptoms (WHI).

Topical vaginal estrogen improves OAB, GSM, and recurrent UTI in postmenopausal women.

Beers Criteria flag: oxybutynin (immediate-release) — high anticholinergic burden, dementia association; prefer mirabegron or trospium in elderly.

Mirabegron caution: check BP; avoid in uncontrolled HTN; CYP2D6 interaction with metoprolol.

Third-line OAB ladder: Botox → PTNS → sacral neuromodulation.

Midurethral sling = gold standard for SUI surgery; mesh slings remain standard despite FDA actions against transvaginal mesh for prolapse.

Urethral diverticulum triad — "3 Ds": Dysuria, post-void Dribbling, Dyspareunia + anterior vaginal wall tender mass.

Continuous leakage post-hysterectomy → think vesicovaginal fistula; tampon dye test, cystoscopy.

PVR >150–200 mL → don't start anticholinergics; investigate overflow.

Cauda equina red flags: new incontinence + saddle anesthesia + leg weakness → emergent MRI.

PFMT is first-line for stress, urge, and mixed incontinence — at least 8–12 weeks.

3-day bladder diary is the highest-yield outpatient tool.

Bladder cancer — painless hematuria in older woman, especially smoker; cystoscopy + CT urogram.

Nocturia >2/night → independent fall and fracture risk; consider OSA, HF, evening fluids, diuretic timing.

Cesarean reduces but doesn't eliminate stress incontinence risk vs vaginal delivery.

Asymptomatic bacteriuria: treat in pregnancy, don't treat in non-pregnant women — including those with incontinence.

CAUTI is a CMS never-event — never use Foley to manage incontinence.

Board Question Stem Patterns

— "65-year-old multiparous woman leaks urine with coughing, sneezing, laughing for 2 years. PVR 30 mL. UA normal. Next step?"

— Answer: Pelvic floor muscle training (and weight loss if BMI elevated) — not urodynamics, not sling, not anticholinergic.

— "78-year-old with sudden urgency, occasional leakage en route to bathroom, nocturia ×3. Mild memory issues. Next pharmacologic step after behavioral therapy?"

— Answer: Mirabegron — avoid oxybutynin (Beers, cognition).

— "82-year-old admitted for pneumonia develops new incontinence on hospital day 3. On haloperidol for delirium, lorazepam at night, ceftriaxone, and IV fluids. Most appropriate next step?"

— Answer: Identify and reverse DIAPPERS — stop sedatives, treat delirium, mobilize, check for impaction — not start antimuscarinic.

— "62-year-old smoker with urgency and microscopic hematuria on UA. Next step?"

— Answer: Cystoscopy + CT urogram for bladder cancer workup, not OAB therapy.

— "45-year-old reports continuous urine leakage 3 weeks after total abdominal hysterectomy for fibroids."

— Answer: Vesicovaginal fistula — confirm with tampon/dye test or cystoscopy; urogynecology referral.

— "32-year-old with urgency, frequency, intermittent visual blurring, and lower-extremity numbness."

— Answer: MRI brain and spine for MS.

— "Elderly woman with stroke and incontinence has indwelling Foley placed for skin protection. Develops fever and pyuria. Best management strategy going forward?"

— Answer: Remove Foley, treat UTI, institute scheduled toileting and external collection device — Foley is not appropriate for incontinence.

— "Woman started on lisinopril develops new stress incontinence."

— Answer: Switch to ARB — ACEi cough provokes stress leakage.

— "2 years post-sling, woman has vaginal bleeding and partner reports sharp sensation during intercourse."

— Answer: Mesh exposure — refer to urogynecology for evaluation and possible excision.

Step 3 management: When in doubt on Step 3, choose behavioral/lifestyle + reversible-cause workup first, then targeted drug, then specialist referral — premature surgery or invasive testing is almost always wrong.

Pattern 1 — The classic SUI workup:

Pattern 2 — The urgency stem in an elderly woman:

Pattern 3 — The reversible cause trap:

Pattern 4 — The hematuria pivot:

Pattern 5 — The post-hysterectomy fistula:

Pattern 6 — The MS red flag:

Pattern 7 — The Foley misuse:

Pattern 8 — The cough/ACE inhibitor:

Pattern 9 — The mesh-sling complication:

One-Line Recap

Urinary incontinence in women is a common, underreported, and highly treatable condition where the correct Step 3 approach is to classify subtype by targeted history, screen and reverse DIAPPERS causes, exclude red flags with UA and PVR, and start lifestyle modification plus pelvic floor muscle training before escalating to subtype-directed pharmacotherapy or procedural care.

Board pearl: The Step 3 winning move is almost always behavioral therapy + reversible-cause review first, drugs second, procedures third — and topical vaginal estrogen is a high-yield "easy win" answer for postmenopausal women with urinary symptoms.

Diagnosis is clinical: history + cough stress test + UA + PVR + 3-day bladder diary classifies most patients; urodynamics and cystoscopy are reserved for failed therapy, hematuria, prior surgery, or neurologic disease.

First-line is always behavioral: weight loss, caffeine reduction, smoking cessation, bowel regimen, scheduled voiding, and pelvic floor muscle training for 8–12 weeks — applies to stress, urge, and mixed incontinence.

Pharmacology is subtype-specific: mirabegron or antimuscarinics for urgency (prefer mirabegron or trospium in elderly per Beers); topical vaginal estrogen for postmenopausal genitourinary symptoms; no good drug for stress (consider pessary or sling). Avoid systemic estrogen — it worsens incontinence.

Escalate appropriately: third-line OAB ladder is Botox → PTNS → sacral neuromodulation; midurethral sling remains gold standard for refractory SUI; never use indwelling Foley for incontinence management (CAUTI risk, CMS never-event); investigate hematuria, continuous leakage, and new neurologic findings urgently.